SWOG clinical trial number
S1714
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
Closed
Phase
Accrual
100%
Abbreviated Title
CIPN
Status Notes
S1714 will permanently close to accrual on November 15, 2021 at 12:00 pm PST.
Activated
03/01/2019
Participants
SWOG, ALL NCORP COMPONENTS AND SUBCOMPONENTS
Research committees
Symptom Control and Quality of Life
Breast Cancer
Lung Cancer
Early Therapeutics & Rare Cancers
Other Study Materials
Eligibility Criteria Expand/Collapse
- Stage I, II, or III primary non-small cell lung, primary breast, or primary ovarian cancer.
- Planning to start treatment with a taxane-based chemotherapy as part of one of the study-approved taxane regimens within 14 days after reg. See Appendix 18.1 for the study-approved docetaxel and paclitaxel-based regimens.
- Treatment on another clinical trial is allowed if it is one of the study-approved regimens listed in Appendix 18.1. Additional treatments (i.e., experimental therapy, immunotherapy, biologics, etc.) as part of another clinical trial in addition to any regimen approved in this study is allowed.
- No prior taxane, platinum, vinca alkaloid, or bortezomib-based chemotherapy regimen. (Carboplatin-containing regimen after reg as part of the docetaxel or paclitaxel regimen is allowed.)
- >/= 18 years of age.
- Must be able to complete Patient-Reported Outcome (PRO) instruments in English or Spanish. Must: 1) agree to complete PROs at all scheduled assessments; and 2) complete the baseline PRO forms prior to reg.
- Pre-existing neuropathy is allowed (incl. diabetes and neurological conditions).
- Must agree to submit required specimens for defined translational medicine.
- Must be offered the opportunity to submit additional optional specimens for future, unspecified translational medicine and banking. With consent, specimens must be submitted.
- Must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
- Planning to start treatment with a taxane-based chemotherapy as part of one of the study-approved taxane regimens within 14 days after reg. See Appendix 18.1 for the study-approved docetaxel and paclitaxel-based regimens.
- Treatment on another clinical trial is allowed if it is one of the study-approved regimens listed in Appendix 18.1. Additional treatments (i.e., experimental therapy, immunotherapy, biologics, etc.) as part of another clinical trial in addition to any regimen approved in this study is allowed.
- No prior taxane, platinum, vinca alkaloid, or bortezomib-based chemotherapy regimen. (Carboplatin-containing regimen after reg as part of the docetaxel or paclitaxel regimen is allowed.)
- >/= 18 years of age.
- Must be able to complete Patient-Reported Outcome (PRO) instruments in English or Spanish. Must: 1) agree to complete PROs at all scheduled assessments; and 2) complete the baseline PRO forms prior to reg.
- Pre-existing neuropathy is allowed (incl. diabetes and neurological conditions).
- Must agree to submit required specimens for defined translational medicine.
- Must be offered the opportunity to submit additional optional specimens for future, unspecified translational medicine and banking. With consent, specimens must be submitted.
- Must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
Publication Information Expand/Collapse
2022
Other Clinical Trials
SWOG Clinical Trial Number
S2206
A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
8%
Open
Phase
SWOG Clinical Trial Number
S2212
TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
14%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007
A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase